DNA sequencing company 23andMe has decided to suspend its testing services following a complaint from the Food and Drug Administration questioning the accuracy of the service and its effects on self-diagnosis. In a blog post, 23andMe founder Anne Wojcicki explained the situation: I am highly disappointed that we have reached this point and will work hard to make sure consumers have direct access to health information in the near future. Our goal is to work cooperatively with the FDA to provide that opportunity. Our lab partner adheres to strict quality standards that are part of the Clinical Laboratory Improvement Amendments of 1988 — known as CLIA.
Comments are closed.
